Complete Wegovy vs Mounjaro Switching Guide & Comparison
Understanding The Switch From Mounjaro To Wegovy: Key Mechanism Differences
When switching from Mounjaro to Wegovy, how long to wait depends largely on understanding their distinct mechanisms of action. Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics your body's natural fullness hormone, whilst Mounjaro contains tirzepatide, a dual GIP and GLP-1 receptor agonist. This fundamental difference affects how your body responds to each treatment and influences the transition timeline your prescriber will recommend.
The switching process from Mounjaro to Wegovy requires careful consideration of washout periods and dose equivalencies. Generally, healthcare professionals recommend allowing one week between your last Mounjaro injection and starting Wegovy, though this can vary based on individual response and current dose levels. Your prescriber will assess factors including your current Mounjaro dose, how long you've been on treatment, and any side effects experienced to determine the most appropriate switching timeline for your circumstances.
Wegovy vs Mounjaro Pricing: Complete Cost Comparison When Switching
Understanding the cost implications when switching from Mounjaro to Wegovy helps plan your treatment budget effectively. Wegovy pricing at EverydayMeds starts with the 0.25mg starter dose at £79.99, progressing through 0.5mg at £94.99, 1mg at £99.99, 1.7mg at £139.99, to the maintenance 2.4mg dose at £209.99. New customers benefit from code FIRST40, whilst returning customers use DOSE25, with these discounts already reflected in our listed prices.
Our Getting Started bundles provide particular value for those switching from Mounjaro to Wegovy, with the Intro Duo (0.25mg & 0.5mg) priced at £169.99 covering your first 8 weeks of treatment. The Progress Trio bundle at £369.99 includes 0.5mg, 1mg and 1.7mg doses, providing 12 weeks of dose escalation. For patients reaching maintenance, our Ultimate Stability Trio offers three 2.4mg pens at £649.99, ensuring consistent supply without frequent reordering from our GPhC-registered pharmacy (#9012878).
Clinical Evidence Supporting The Switch: STEP Trial Data
When considering switching from Mounjaro to Wegovy, clinical evidence from the STEP programme demonstrates semaglutide's effectiveness in weight management. In the pivotal STEP 1 trial published by Wilding et al. in the New England Journal of Medicine (2021), patients taking Wegovy alongside diet and exercise achieved an average weight loss of approximately 15% at 68 weeks, compared to 2.4% with placebo. The SELECT cardiovascular outcomes trial further showed a 20% reduction in major cardiovascular events.
These clinical results provide reassurance for patients switching from Mounjaro to Wegovy that semaglutide offers robust evidence for sustained weight management. However, individual responses vary, and your prescriber will monitor your progress closely during the transition period. The STEP trials demonstrate that Wegovy works optimally as part of a comprehensive approach including reduced-calorie diet and increased physical activity, factors that remain crucial when switching between treatments.
How Wegovy Works: GLP-1 Mechanism For Switching Patients
Understanding how Wegovy works helps patients switching from Mounjaro to Wegovy appreciate the treatment differences. Semaglutide functions as a GLP-1 receptor agonist, binding to receptors in your brain's appetite control centres to promote feelings of fullness and reduce food cravings. Unlike Mounjaro's dual-hormone approach, Wegovy focuses specifically on the GLP-1 pathway, which many patients find provides consistent appetite suppression. The once-weekly injection delivers sustained semaglutide levels, working continuously to support portion control and reduce between-meal snacking. This mechanism explains why some patients prefer switching from Mounjaro to Wegovy, particularly if they found tirzepatide's dual action less suitable for their response pattern.
Ordering Process When Switching From Mounjaro To Wegovy
The process for switching from Mounjaro to Wegovy through EverydayMeds begins with our 3-minute online clinical assessment, where you'll indicate your current treatment history and reasons for switching. Our prescribers review your case within 3 working days (or 24 hours with express service), considering factors like your previous response to Mounjaro, any side effects experienced, and your treatment goals. Once approved, your Wegovy prescription is dispatched via next-day cold-chain delivery, maintaining the 2-8°C temperature requirements throughout transport. You'll receive the FlexTouch pen system with comprehensive injection guidance, plus our patient support materials covering the switching timeline. This streamlined process ensures minimal treatment interruption when transitioning between medications.
Storage Advantages: Wegovy vs Mounjaro Practical Differences
A key practical advantage when switching from Mounjaro to Wegovy lies in storage flexibility, particularly important for frequent travellers. Wegovy pens maintain efficacy for 6 weeks at room temperature (below 30°C) once removed from refrigeration, compared to Mounjaro's 21-day limit. This extended room temperature stability makes Wegovy more convenient for holidays, business travel, or situations where refrigeration isn't readily available. The FlexTouch pen design provides consistent dose delivery throughout this period, whilst the dose escalation schedule (0.25mg to 2.4mg over 17+ weeks) allows for gradual adjustment as your body adapts from Mounjaro's different dosing pattern.
Transition Timeline: Managing The Switch From Mounjaro To Wegovy
The specific timeline for switching from Mounjaro to Wegovy depends on individual factors including your current dose, treatment duration, and side effect profile. Most prescribers recommend a one-week washout period between your final Mounjaro injection and first Wegovy dose, though some patients may require longer intervals based on their response history. During this transition, maintaining your established diet and exercise routine helps ensure treatment continuity.
Your prescriber will typically restart Wegovy at the 0.25mg dose regardless of your previous Mounjaro dose, following the established escalation schedule through 0.5mg, 1mg, 1.7mg to maintenance 2.4mg. This gradual approach minimises potential gastrointestinal side effects that can occur when switching between GLP-1 based treatments. Regular monitoring during the first 8-12 weeks helps optimise your individual switching experience.
Complete Treatment Support: Both Options Available
At EverydayMeds, we understand that switching from Mounjaro to Wegovy represents an important treatment decision requiring expert guidance and ongoing support. Our GPhC-registered pharmacy (#9012878) stocks both medications, allowing your prescriber to recommend the most appropriate option based on your individual circumstances, previous treatment response, and lifestyle factors. Whether you continue with Mounjaro or switch to Wegovy, our clinical team provides comprehensive support throughout your weight management journey.
Both Wegovy and Mounjaro are available through our secure online platform, with the same rigorous clinical assessment process and next-day cold-chain delivery service. Your prescriber can help determine the optimal switching timeline, monitor your transition progress, and adjust treatment plans as needed. This flexibility ensures you receive the most appropriate prescription-only medicine for your individual weight management goals. Start your clinical assessment today to discuss switching options with our qualified prescribers.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
